Repligen | RGEN - Actif À Court Terme





Actif À Court Terme Changement Date
Agilent USD 4.62B 21M 2025-12
Align Technology USD 2.66B 38.87M 2026-03
Bio Techne USD 637.43M 27.92M 2025-12
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Bruker USD 2.21B 138.1M 2025-12
Charles River Laboratories USD 1.45B 85.06M 2025-12
Danaher USD 13.94B 1.18B 2026-03
Dentsply International USD 1.85B 178M 2026-03
General Electric Aerospace USD 40.36B 235M 2026-03
Henry Schein USD 4.5B 32M 2026-03
Illumina USD 2.74B 551M 2026-03
IQVIA Holdings USD 6.22B 29M 2026-03
Mettler Toledo International USD 1.36B 81.46M 2025-12
Myriad Genetics USD 332.6M 12.2M 2025-12
OraSure Technologies USD 261.91M 21.1M 2025-12
Pacific Biosciences Of California USD 375.05M 19.18M 2025-12
Pfizer USD 42.82B 76M 2026-03
Repligen USD 1.14B 40.9M 2025-12
Revvity USD 2.24B 95.96M 2025-12
Standard Biotools USD 454.26M 18.18M 2025-12
Thermo Fisher Scientific USD 22.32B 6.39B 2026-03
Waters USD 1.99B 69.86M 2025-12
West Pharmaceutical Services USD 1.83B 151.4M 2026-03